MediciNova, Inc. (MNOV) Forms $13.23 Double Top; 1 Analysts Bullish Sanofi (SNY)

Sanofi (NYSE:SNY) Logo

MediciNova, Inc. (MNOV) formed double top with $14.02 target or 6.00% above today’s $13.23 share price. MediciNova, Inc. (MNOV) has $541.48M valuation. The stock increased 5.00% or $0.63 during the last trading session, reaching $13.23. About 148,806 shares traded. MediciNova, Inc. (NASDAQ:MNOV) has risen 98.80% since April 10, 2017 and is uptrending. It has outperformed by 87.25% the S&P500.

Among 12 analysts covering Sanofi-aventis Sa (NYSE:SNY), 1 have Buy rating, 2 Sell and 9 Hold. Therefore 8% are positive. Sanofi-aventis Sa had 25 analyst reports since October 15, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Monday, December 18 with “Hold”. The stock of Sanofi (NYSE:SNY) earned “Hold” rating by Cowen & Co on Friday, October 13. The stock has “Hold” rating by Bank of America on Wednesday, December 6. Cowen & Co maintained it with “Hold” rating and $52.0 target in Tuesday, September 5 report. The firm has “Equal-Weight” rating given on Wednesday, November 15 by Barclays Capital. The company was upgraded on Wednesday, April 12 by JP Morgan. The rating was initiated by Goldman Sachs on Monday, November 7 with “Neutral”. The stock has “Buy” rating by Berenberg on Thursday, September 8. Argus Research initiated it with “Buy” rating and $50.0 target in Thursday, April 6 report. Berenberg downgraded the shares of SNY in report on Thursday, May 11 to “Hold” rating. See Sanofi (NYSE:SNY) latest ratings:

08/02/2018 Broker: Bernstein Rating: Hold New Target: $45.0 Maintain
23/01/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Downgrade
18/12/2017 Broker: Cowen & Co Rating: Hold New Target: $48.0 Maintain
06/12/2017 Broker: Bank of America Rating: Hold Downgrade
01/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Underweight Downgrade
15/11/2017 Broker: Barclays Capital Old Rating: Underweight New Rating: Equal-Weight Upgrade
13/10/2017 Broker: Cowen & Co Rating: Hold New Target: $52.0 Maintain

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $101.24 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It has a 10.02 P/E ratio. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

The stock increased 1.03% or $0.42 during the last trading session, reaching $41.15. About 951,155 shares traded. Sanofi (NYSE:SNY) has declined 13.31% since April 10, 2017 and is downtrending. It has underperformed by 24.86% the S&P500.

Among 2 analysts covering Medicinova (NASDAQ:MNOV), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Medicinova has $2200 highest and $22 lowest target. $22’s average target is 66.29% above currents $13.23 stock price. Medicinova had 2 analyst reports since March 28, 2018 according to SRatingsIntel. The company was initiated on Wednesday, March 28 by FBR Capital.

MediciNova, Inc. (NASDAQ:MNOV) Institutional Positions Chart